PCAS ALLOCATION OF FREE SHARES
Longjumeau, May 24, 2016
Exercising the authorization granted by the Shareholders' Meeting of April 21, 2016, and in keeping with the profit-sharing policy implemented previously, the meeting of the PCAS Board of Directors of May 11, 2016 decided to complete its allocation of free shares in favor of new beneficiaries.
The new allocations represent 156,204 shares that can be acquired until May 2019, with a retention period of one year.
To avoid further dilution of the capital, the decision was also made to allocate these shares, as well as those in previous plans that have not yet been issued, i.e. a total of 530,000 shares, for about 100 beneficiaries, by drawing from the treasury stock (1,480,000 shares), since the shares included in these allocations are held in a dedicated account until they are acquired by the beneficiaries.
About PCAS (Euronext Paris: BCP, eligible for the PEA-PME plan)
PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers of a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. PCAS generated net sales of €179.1 million in 2015 and employs close to 900 people in six countries.
To find out more about PCAS, visit: www.pcas.com
PCAS
Vincent Touraille / Eric Moissenot
Tel.: +33 1 69 79 61 32
www.pcas.com
NewCap
Emmanuel Huynh / Louis-Victor Delouvrier
Financial communication and Investor Relations
Tel.: +33 1 44 71 94 94
pcas@newcap.eu
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCAS via Globenewswire
